Clinical Trial Update: Study of Velcade® and Bone Formation in Patients With Relapsed/Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 study evaluating Velcade (bortezomib) in relapsed/refractory multiple myeloma with bone-formation outcomes; the trial was terminated with results posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Velcade (bortezomib)

Snippet

Sponsor: University of Arkansas | Conditions: Multiple Myeloma | Phase 2 | Status: TERMINATED | Results posted: 2012-04-26